12 months PFS rate [95%CI] | p value | 12 months OS rate [95%CI] | p value | |
---|---|---|---|---|
Age (years) | ||||
< 65 | 24.6 [14.1–43.1] | 0.01 | 83.8 [73.4–95.7] | 0.3 |
≥ 65 | 30.8 [17.9–53] | 89 [80.3–98.75] | ||
Performance status | ||||
0–1 | 36.7 [27.5–49] | 0.5 | 88.8 [82.1–96] | 0.05 |
2 | 0 | 56.2 [28.1–100] | ||
Grade | ||||
< 3 | 38.1 [27.6–52.6] | 0.2 | 85.4 [76.9–94.8] | 0.7 |
≥ 3 | 23.2 [10.9–49.1] | 86.8 [74–100] | ||
PR status | ||||
Negative | 35.7 [21.4–59.5] | 0.5 | 80.3 [66.1–97.6] | 0.1 |
Positive | 33.8 [23.5–48.7] | 88.9 [81.3–97.1] | ||
Synchronous metastasis | ||||
No | 37.7 [27–52.7] | 0.05 | 95.3 [90.3–100] | 0.07 |
Yes | 27.8 [15–51.4] | 68 [52.7–87.9] | ||
Visceral metastasis | ||||
No | 39.5 [25.3–61.6] | 0.6 | 80.4 [67.3–96] | 0.7 |
Yes | 27.8 [15–51.4] | 89.5 [81.8–97.9] | ||
Primary endocrine resistance | ||||
No | 40.4 [30.3–53.8] | 0.02 | 90.2 [83.5–97.5] | 0.01 |
Yes | 11.8 [3.2–43.2] | 69 [49.7–95.8] | ||
Previous chemotherapy | ||||
No | 49.7 [36.2–68.4] | < 0.001 | 100% - No death | 0.01 |
1 or 2 lines | 35.1 [21.1–58.2] | 76.6 [62.8–93.6] | ||
≥ 3 lines | 4.8 [0.7–32.2] | 74.8 [57.8–96.7] | ||
pTKa at baseline* | HR = 1.3 [1.2–1.5] | < 0.0001 | HR = 1.4 [1.2–1.6] | 0.0006 |
pTKa at 4 weeks* | HR = 1.3 [1.1–1.5] | 0.01 | HR = 1.5 [1.2–1.8] | 0.0003 |
Variation of pTKa between baseline and 4 weeks | ||||
Increase | 30.4 [17.6–52.3] | 0.9 | 75 [60.1–93.7] | 0.2 |
Decrease | 34.2 [22.6–51.6] | 90.7 [82.4–99.9] |